Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2018-01-19 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a specific regulatory event: the U.S. FDA granting Priority Review for daratumumab, including a PDUFA date. It is a formal communication from the company (Genmab A/S) to the market regarding a significant regulatory milestone and clinical trial data summary. This type of announcement, which is not a full financial report (like 10-K or IR), nor a transcript (CT), nor a proxy statement (DEF 14A), nor a pure dividend notice (DIV), fits best under the general category of a significant corporate event announcement. Since it is a formal, non-financial regulatory update that doesn't fit the other specific categories (like M&A, Capital Change, or Director Dealing), it is classified as a Regulatory Filing (RNS), which serves as the general category for important, non-standardized regulatory news releases.
2018-01-19 English
U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing FDA Priority Review for a drug application (sBLA) and providing clinical and company background. It contains no financial statements, management changes, share transactions, or detailed report attachments. It is a general regulatory announcement regarding FDA review status rather than an annual/interim report or earnings release. Therefore, it best fits the fallback category for miscellaneous regulatory announcements.
2018-01-19 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled "Major Shareholder Announcement" and details a change in ownership stake by Artisan Partners Limited Partnership, crossing the 5% threshold, referencing the Danish Securities Trading Act. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels. Filing Category Match: Major Shareholding Notification (Code: MRQ).
2018-01-09 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 95% confidence The document is a company announcement under Section 29 of the Danish Securities Trading Act reporting that Artisan Partners has increased its indirect ownership in Genmab A/S to 5.04% of share capital and voting rights. This is a notification of crossing a significant shareholding threshold. Therefore it falls under Major Shareholding Notification (MRQ).
2018-01-09 English
Director's Dealing 2018
Director's Dealing Classification · 98% confidence The document text is a template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details specific transactions (Acquisition due to vesting of restricted stock units) made by individuals holding positions like 'Chairman of the Board of Directors' and 'President & Chief Executive Officer' of the issuer 'Genmab A/S'. This content directly corresponds to the reporting requirements for insider trading or executive share transactions, which aligns with the definition of Director's Dealing (DIRS).
2018-01-02 English
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document text is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details transactions (specifically 'Grant of Restricted Stock Units') made by individuals holding positions like 'Chairman of the Board of Directors' and 'Member of the Board of Directors' of the issuer, Genmab A/S. This structure perfectly matches the definition of Director's Dealing reports, which track insider trades by management and directors.
2017-12-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.